Stay updated on Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial page.

Latest updates to the Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial page
- Check6 days agoChange DetectedAdded sponsor context and a direct access point to related resources by introducing the Moffitt Cancer Center Clinical Trials website and sponsor name. A 'Helpful Links Provided by' label now appears to guide users to additional resources.SummaryDifference0.1%

- Check13 days agoChange DetectedPage revision updated from v3.6.0 to v3.6.3, indicating a newer published version of the study details page. This reflects an update in the revision history (likely content or metadata changes) rather than a visible change to the page's substantive content.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRecruitment status now indicates enrollment is closed. The page adds new helper sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the Intervention/Treatment header and revision label to v3.6.0, replacing the prior heading and v3.5.5 reference.SummaryDifference0.4%

- Check34 days agoChange DetectedA new site revision label v3.5.5 has been added, replacing the previous v3.5.4. This update reflects a minor platform release and does not modify the study content or user-facing information.SummaryDifference0.0%

- Check41 days agoChange DetectedDeleted sponsor/affiliate identifiers ('Moffitt Cancer Center Clinical Trials website' and 'H. Lee Moffitt Cancer Center and Research Institute') and the 'Helpful Links Provided by' heading, changing how institutional affiliation and sponsor-related resources are presented on the study page.SummaryDifference0.1%

- Check48 days agoChange DetectedA new Publications entry has been added, documenting a 2026 Am J Clin Oncol article evaluating neutrophil-to-lymphocyte ratio in patients treated with cetuximab and nivolumab for recurrent/metastatic head and neck squamous cell carcinoma.SummaryDifference0.0%

Stay in the know with updates to Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cetuximab & Nivolumab in Head & Neck Cancer Clinical Trial page.